https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15295 Wed 11 Apr 2018 16:20:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11542 Wed 11 Apr 2018 15:09:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9218 65 years of age) drivers (pooled OR 1.13; 95% CI 0.97, 1.31) than in drivers <65 years of age (pooled OR 2.21; 95% CI 1.31, 3.73), a result consistent with age-stratified risk differences reported in cohort studies. Anxiolytics, taken in single or multiple doses during the daytime, impaired driving performance independent of their half-lives. With hypnotics, converging evidence from experimental and epidemiological studies indicates that diazepam, flurazepam, flunitrazepam, nitrazepam and the short half-life non-benzodiazepine hypnotic zopiclone significantly impair driving, at least during the first 2–4 weeks of treatment. The accident risk was higher in the elderly (>65 years of age) who use tricyclic antidepressants (TCAs); however, the evidence for an association of antidepressants with accident risk in younger drivers was equivocal. Sedative but not non-sedative antidepressants were found to cause short-term impairment of several measures of driving performance. Limited epidemiological research reported that opioids may be associated with increased accident risk in the first few weeks of treatment. Conclusions: Benzodiazepine use was associated with a significant increase in the risk of traffic accidents and responsibility of drivers for accidents. The association was more pronounced in the younger drivers. The accident risk was markedly increased by co-ingestion of alcohol. Driving impairment was generally related to plasma half-lives of hypnotics, but with notable exceptions. Anxiolytics, with daytime dosing, impaired driving independent of their half-lives. TCAs appeared to be associated with increased accident risk, at least in the elderly, and caused short-term impairment in driving performance. Opioid users may be at a higher risk of traffic accidents; however, experimental evidence is limited on their effects on driving.]]> Wed 11 Apr 2018 14:30:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11541 Wed 11 Apr 2018 13:32:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11302 Wed 11 Apr 2018 12:24:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43082 Tue 13 Sep 2022 12:19:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28795 15% reduction over their own baseline breathlessness intensity. Results: Eleven people had trial medication (eight males, median age 78 years (68 to 89); all had COPD; median Karnofsky 70 (50 to 80); six were on long-term home oxygen. Ten people completed day four. One person withdrew because of unsteadiness on day four. Five participants reached the 15% reduction, but only three went on to the extension study, all completing without toxicity. Conclusion: This study was safe, feasible and there appears to be a group who derive benefits comparable to titrated opioids. Given the widespread use of benzodiazepines for the symptomatic treatment of chronic refractory breathlessness and its poor evidence base, there is justification for a definitive phase III study.]]> Sat 24 Mar 2018 07:38:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42327 Mon 22 Aug 2022 10:03:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34254 Fri 22 Feb 2019 16:55:18 AEDT ]]>